Exclusive Summary

• Moxifloxacin HCl ophthalmic solution's original patent has expired, leading to a mature imitation market with moderate competition.
• Bacterial conjunctivitis and keratitis are globally prevalent ocular infections, ensuring stable and growing market demand.
• The product is listed in the WHO Essential Medicines List and recommended as a first-line or important treatment in clinical guidelines, indicating high clinical value.
• Compared to the originator drug, it offers a significant cost advantage while maintaining efficacy and safety.
• Chinese manufacturers possess international quality certifications and extensive registration experience, facilitating rapid market entry.